Delivery Order SPE2DB22D3301-SPE2DB26FX3JP
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on June 3, 2025, for $43,813.23 to supply Enbrel 50 mg/mL SureClick auto-injectors. This non-competitive, firm fixed price delivery order is set to conclude on June 4, 2025, and will be fulfilled at the contractor's corporate office location in Conshohocken, Pennsylvania. The award represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical,...
- The Defense Logistics Agency awarded a $18,507.12 delivery order to AmerisourceBergen Drug Corp on October 16, 2025, for the supply of Enbrel 50 mg/mL SureClick auto-injectors. This firm fixed-price contract, which is expected to be completed by October 17, 2025, was competitively awarded with no set-aside designation. The work will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under the company's existing Indefinite...
- The Defense Logistics Agency awarded a $90,119.95 firm fixed price delivery order to AmerisourceBergen Drug Corp on September 18, 2025, for the supply of ENBREL 50 MG/ML SureClick auto-injectors. This non-competitive delivery order is set to be completed by September 19, 2025, with performance occurring at the vendor's facility in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and critical federal medical procurement vendor, fulfills this order...
- The Defense Logistics Agency awarded a $39,049.72 delivery order to AmerisourceBergen Drug Corp on August 27, 2025, for the supply of Enbrel 50 mg/mL SureClick auto-injectors. This competitively awarded, firm fixed-price contract serves as a child order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The pharmaceutical will be delivered to AmerisourceBergen's corporate office...
- The Defense Logistics Agency awarded a $25,765.04 firm fixed price delivery order to AmerisourceBergen Drug Corp on September 3, 2025, for the supply of ENBREL 50 MG/ML SureClick auto-injectors. The contract, which represents a child order under a larger procurement vehicle, will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania, with an ultimate completion date of September 4, 2025. This delivery order was competitively awarded with no set-aside designation,...
- The Defense Logistics Agency (DLA) awarded a $22,930.02 delivery order to AmerisourceBergen Drug Corp on September 26, 2025, for the supply of Enbrel 50 mg/ml SureClick auto-injectors. This firm fixed-price contract, which is non-set-aside and competitively awarded, is scheduled for completion by September 29, 2025, with performance to be executed at AmerisourceBergen's corporate headquarters in Conshohocken, Pennsylvania. The delivery order is issued under AmerisourceBergen's larger...
- The Defense Logistics Agency awarded a $97,781 delivery order to AmerisourceBergen Drug Corp for Enbrel 50 mg/mL SureClick auto-injectors, with an ultimate completion date of September 29, 2025. This non-set-aside, firm fixed price delivery order was competitively awarded on September 26, 2025, with performance to be fulfilled at AmerisourceBergen's Conshohocken, Pennsylvania facility. The award represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA...
- The Defense Logistics Agency (DLA) awarded a $35,072.01 delivery order to AmerisourceBergen Drug Corp for Enbrel 50 mg/mL SureClick auto-injectors, with an ultimate completion date of August 21, 2025. This non-set-aside, competitively awarded contract utilizes firm fixed pricing and represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999 through December 2026. The place of performance is listed...
- The Defense Logistics Agency awarded a $62,786.46 firm fixed-price delivery order to AmerisourceBergen Drug Corp on September 12, 2025, for the supply of ENBREL 50 mg/ml SureClick auto-injectors. This competitively awarded, non-set-aside contract is scheduled for ultimate completion by September 15, 2025, with fulfillment performed at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. The delivery order represents a child contract action under AmerisourceBergen's larger...
- The Defense Logistics Agency awarded a $52,670.24 delivery order to AmerisourceBergen Drug Corp for Enbrel 50 mg/ml SureClick auto-injectors, with a completion date of September 8, 2025. This competitively awarded, firm fixed-price contract carries no set-aside designation and represents a child order under AmerisourceBergen's larger pharmaceutical supply agreement with DLA. The product will be delivered to the contractor's facility in Conshohocken, Pennsylvania, where AmerisourceBergen...
- SPE2DB22D3301Indefinite Delivery Contract
- SPE2DB22D3301-SPE2DB26FX3JPDelivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on October 16, 2025, for $145.4K to supply Enbrel 50 mg/ml SureClick auto-injectors to support federal medical procurement needs. This non-competitive, firm fixed-price delivery order is expected to be completed by October 17, 2025, and will be fulfilled from the vendor's Conshohocken, Pennsylvania location. The award represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated as SPE2DX and valued at $999.9M through December 2026, which serves as the primary vehicle for pharmaceutical and medical supply distribution to military and federal healthcare systems worldwide. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Pennsylvania, holds a strategic position within the Defense Logistics Agency's medical supply chain. As a competitively awarded prime contractor, the company supplies a comprehensive portfolio of brand-name and generic medications, vaccines, and medical devices across multiple therapeutic domains to support military healthcare programs globally. This delivery order for Enbrel, a TNF inhibitor used in rheumatologic treatments, exemplifies the company's role in fulfilling specialized pharmaceutical requirements for the Defense Health Agency and other federal healthcare systems through the broader SPE2DX platform.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $145.4k | 10/16/25 |